JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Identification of cancer-associated fibroblast-related Ectodysplasin-A as a novel indicator for prognosis and immune response in gastric cancer

  • 0Department of Pathology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
Heliyon +

|

August 2, 2024

|

August 2, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Cancer-associated fibroblasts (CAFs) influence gastric cancer (GC) progression. Researchers identified EDA as a potential biomarker for GC, linked to poor survival and immune regulation, suggesting it as a therapeutic target.

Area Of Science

  • Oncology
  • Molecular Biology
  • Immunology

Background

  • Cancer-associated fibroblasts (CAFs) play a critical role in gastric cancer (GC) progression and chemotherapy resistance.
  • Identifying specific CAF-related genes as biomarkers for GC occurrence remains an area needing further exploration.

Purpose Of The Study

  • To identify novel cancer-associated fibroblast (CAF) related genes that can serve as biomarkers for gastric cancer (GC) occurrence and prognosis.
  • To investigate the functional role of identified genes in GC progression, chemotherapy resistance, and immune microenvironment.

Main Methods

  • Analysis of two Gene Expression Omnibus (GEO) datasets to identify differentially expressed genes.
  • Utilized COX regression, LASSO regression, and Kaplan-Meier survival analysis to identify prognostic genes.
  • Performed single-cell analysis, nomogram construction, immunohistochemistry (IHC), and real-time PCR to validate findings and explore functional roles.

Main Results

  • Identified three upregulated genes (GLT8D2, GNAS, EDA) significantly associated with poor GC patient survival.
  • Found that EDA expression correlates with fibroblast production, poorer GC prognosis, and increased 5-Fluorouracil IC50 values.
  • EDA levels were elevated in GC tissues and cells, linked to immune system regulation, FGF12 expression, and interferon-gamma response.

Conclusions

  • EDA may serve as a novel diagnostic and prognostic biomarker for gastric cancer (GC).
  • EDA's association with fibroblast markers and immune responses suggests its potential as a therapeutic target in GC treatment.
  • Further research into EDA's role in the tumor microenvironment could reveal new therapeutic strategies for GC.

Keywords: